Navigation Links
Alimera Sciences Reports First Quarter 2013 Financial Results
Date:5/9/2013

al corporate purposes. The line of credit will be utilized to finance eligible accounts receivable in the United Kingdom, Germany and France, and replaces the $20 million line of credit previously provided by SVB to finance accounts receivable in the United States.  Alimera believes this debt facility strengthens its financial position for the commercialization of ILUVIEN® in the United Kingdom, Germany and France and provides additional resources as management evaluates its expansion plans in Europe.

Conference Call to be Held TodayAlimera will hold a conference call today at 4:30 PM ET to discuss these results and provide regulatory and commercial updates.  The conference call will be hosted by Dan Myers, president and chief executive officer, and Rick Eiswirth, chief operating officer and chief financial officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at www.alimerasciences.com.

A replay of the conference call will be available beginning May 9, 2013 at 7:30 p.m. ET and ending on May 15, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 64145879. A replay of the webcast will be available on the corporate website for one week, through May 15, 2013.

About Alimera Sciences, Inc.Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

 For inve
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alimera Sciences Secures $20 Million Debt Facility
2. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
3. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
4. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
5. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
6. Alimera Sciences Names European Management Team
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
9. Sangamo BioSciences Reports First Quarter 2013 Financial Results
10. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
11. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 UBM Medica US announces that ... and information resource for neurologists and other healthcare providers, features ... disease , with discussions of the latest developments in approaches ... have Parkinson disease , more than the total of those ... disease. Diagnosis can be difficult because there are no ...
(Date:10/17/2014)... DALLAS , October 17, 2014 /PRNewswire/ ... research report "Optical Imaging Market by Technique (Optical ... System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, ... by MarketsandMarkets, this report studies the Optical Imaging ... The market was valued at $917.1 million ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... PHILADELPHIA, Sept. 9 Compliance Implementation Services (CIS), ... it has been named to Inc. Magazine,s fourth ... companies in the United States. (Logo: ... ) "The leaders of the companies ...
... have an increased risk of developing venous thromboembolism (VTE) due to ... model to predict their chance of developing blood clots, according to ... the journal of the American Society of Hematology. VTE, the formation ... percent of cancer patients and is one of the leading causes ...
Cached Medicine Technology:Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America 2Improvement in Prediction of Blood Clots in Cancer Patients 2Improvement in Prediction of Blood Clots in Cancer Patients 3
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 19, 2014 Dr. Babatunde Osotimehin, ... welcomes news of a ceasefire agreement that is expected ... 200 girls who were kidnapped from the north-eastern Nigerian ... in captivity long enough, and it is high time ... stated Dr. Osotimehin. , "We owe it to these ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... worldwide as the standard of care for a serious lung ... should not be used together to treat the disease, called ... rigorous independent study. The study, which will appear online ... to coincide with a presentation at the annual meeting ...
... Rosenfeld, M.D., M.P.H., of Seattle Children,s Hospital, and colleagues conducted ... rate of pulmonary exacerbations in children younger than 6 years ... recommended as therapy for patients 6 years or older with ... younger than 6 years. In the randomized trial, the ...
... obstructive sleep apnea (OSA) in children normalizes disturbances in ... according to a new study. "OSA is ... and executive function," said lead author Ann Halbower, MD, ... University of Colorado Denver. "Our study is the first ...
... Preliminary results from an ongoing, large-scale study by Yale ... naturally occurring substance produced in the brain and throughout ... known to process social information in children and adolescents ... Child Study Center research team that includes postdoctoral fellow ...
... News) -- Female athletes take longer to recover from ... have longer recovery times. The findings show that doctors ... into account when treating patients with concussions, said researchers ... from nearly 300 athletes in the United States who ...
... News) -- Older men have an increased risk of developing ... not know how to properly check themselves for signs of ... worrisome because nearly 132,000 new cases of melanoma will be ... which conducted the online poll. "This survey demonstrates that ...
Cached Medicine News:Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Treatment of childhood OSA reverses brain abnormalities 2Health News:Oxytocin improves brain function in children with autism 2Health News:Females, Young Athletes Take Longer to Get Over Concussions 2Health News:Melanoma a Big Threat to Older Men 2
... is a modular orthotic elbow system that can ... distal humeral fractures, proximal ulnar fractures or post ... K2 is a highly flexible system that provides ... assemble the brace that best fits your patients ...
The IROM Elbow is ideal for fixed or controlled ROM in the treatment of stable supracondylar fractures, stable radial fractures, and lateral/medial epicondylitis....
A lightweight soft good with rigid elbow protection. Designed by medical professionals with your needs in mind. Provides elbow stability for mild to moderate medial/lateral and hyperextension injurie...
Innovative support that immobilizes and positions elbow at 122 to minimize stretching of ulnar nerve...
Medicine Products: